Every one of those 1 sits in a single category, market-trends. Baldwin is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 3 original sources each against 3.2 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Michael McGarrity
Every one of those 1 sits in a single category, market-trends. Baldwin is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 3 original sources each against 3.2 for the same window. The 5 average consequence score is below the beat benchmark of 5.7 in the same window. We currently track 1 Healthcare story that mention Michael McGarrity, all published on February 27, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Michael McGarrity. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.